Home About Pipeline Team News Contact Us
Our Pipeline

Five programs addressing critical unmet needs in epilepsy & acute care

Each program targets a distinct gap in epilepsy care — from preemptive seizure treatment to disease prevention to neonatal seizure rescue.

Development Status

Pipeline overview

Novel Intranasal Formulation

PrevEp006

Seletracetam

Acute repetitive seizures REST. First non-benzodiazepine intranasal seizure rescue medication.

Novel Network Pharmacology

PrevEp002

Atorvastatin, Ceftriaxone, Levetiracetam

Epilepsy prevention — validated in two models and two species. Network pharmacology approach combining safe, FDA-cleared molecules targeting multiple epileptogenic mechanisms.

PrevEp003 Paused

Levetiracetam, Topiramate, Gabapentin

Epilepsy prevention — validated in a rodent model. Combination therapy targeting multiple epileptogenic mechanisms for post-traumatic epilepsy prevention.

Novel Intravenous Formulation

PrevEp004

IV Topiramate

Neonatal seizures and status epilepticus. Orphan Drug Designation in US and Europe. Safety and efficacy validated in oral formulation1.

PrevEp005 Seeking Outlicense Partner

IV Atorvastatin

First intravenous statin therapy. Novel IV atorvastatin formulation for hospitalized patients unable to take oral statins. Acute statin discontinuation worsens neurologic and cardiac outcomes after ischemic stroke and coronary artery syndromes.

1 Safety and efficacy validated in oral formulation

Supported by NINDS SBIR Awards: 1R43NS132659 & 1R43NS119081

Market Opportunity

Three therapeutic priorities

Addressing the most critical unmet needs across the epilepsy care spectrum.

500K patients/year US

Post-traumatic & Post-stroke Epilepsy

Prevention of epilepsy following traumatic brain injury and stroke.

1.7M patients

Acute Prevention of Seizures

Paradigm shift in epilepsy to preemptive treatment of predictable seizures.

10K babies/year US

Neonatal Seizures

Unmet need: seizure control when standard of care fails.

Lead Program

Intranasal Seletracetam

PrevEp006

A next-generation SV2A ligand with 100x higher potency than levetiracetam (Keppra), delivered intranasally for rapid preemptive treatment of seizures outside the hospital. The first non-benzodiazepine intranasal seizure rescue medication.

  • Intranasal delivery for rapid onset of action
  • At least 10x higher anticonvulsant potency than levetiracetam
  • Non-sedating, non-addictive alternative to benzodiazepines
  • First-in-human data published in Annals of Neurology (2026)

Mechanism of Action

Seletracetam binds to synaptic vesicle glycoprotein 2A (SV2A) with at least 10-fold higher anticonvulsant potency than levetiracetam, modulating neurotransmitter release to prevent seizure propagation.

Intranasal seletracetam spray
Brain neural network
Network Pharmacology

Epilepsy Prevention — Triple Combination

PrevEp002 · Atorvastatin + Ceftriaxone + Levetiracetam

A rational combination of three safe, FDA-cleared molecules targeting multiple epileptogenic mechanisms simultaneously. Validated in two animal models and two species for post-traumatic epilepsy prevention.

  • Uses only FDA-cleared, safety-validated molecules
  • Validated in two animal models and two species
  • Multi-target: neuroinflammation, mTOR, oxidative stress
  • Targets TBI and stroke-induced epileptogenesis

Network Pharmacology Rationale

Epileptogenesis involves multiple converging pathways. Single-target drugs have consistently failed to prevent epilepsy. This combination targets glutamate clearance (ceftriaxone), lipid metabolism and neuroprotection (atorvastatin), and synaptic vesicle regulation (levetiracetam).

Network Pharmacology
Paused

Epilepsy Prevention — Alternative Combination

PrevEp003 · Levetiracetam + Topiramate + Gabapentin

An alternative triple combination therapy validated in a rodent model, offering a different pharmacological profile for post-traumatic epilepsy prevention while maintaining the network pharmacology approach.

  • Alternative pharmacological composition
  • Validated in rodent epilepsy model
  • Focused on post-traumatic epilepsy prevention
  • Uses FDA-cleared, safety-validated molecules
Brain MRI scan
Newborn in NICU with IV treatment
Orphan Drug

IV Topiramate

PrevEp004

A novel intravenous formulation of topiramate for neonatal seizures and status epilepticus. Granted Orphan Drug Designation in both the United States and Europe. Currently there are no FDA-approved treatments for neonatal seizures.

  • FDA Orphan Drug Designation (US & Europe)
  • IV formulation for NICU administration
  • No FDA-approved drugs exist for neonatal seizures
  • Safety and efficacy validated in oral formulation

Clinical Context

Neonatal seizures affect approximately 10,000 babies per year in the US and are associated with increased mortality and lifelong brain damage. Topiramate has demonstrated antiepileptic and neuroprotective properties in oral form — IV administration enables precise dosing in the NICU setting.

Seeking Outlicense Partner

IV Atorvastatin — First Intravenous Statin Therapy

PrevEp005

A novel intravenous atorvastatin formulation for hospitalized patients who are unable to take oral medications. 35–40 million persons take statins daily in the US alone — when unable to swallow, patients must pause statin therapy. Acute statin discontinuation worsens neurologic and cardiac outcomes after ischemic stroke and coronary artery syndromes.

  • First practical IV statin replacement therapy
  • Novel formulation with excellent solubility and bioavailability
  • No competitors — no IV statin approved to date
  • Patent protection through 2039 for novel IV formulations

Regulatory Strategy

Marketing approval based on 505(b)(2) application pathway. Rapid path to standard-of-care with streamlined marketing to hospitalists, surgeons, and critical care physicians.

Intravenous statin therapy
Our Approach

Network Pharmacology

Single-target drugs have failed to prevent epilepsy. Our network pharmacology approach targets multiple epileptogenic mechanisms simultaneously.

Multi-target Strategy

Rational combinations targeting neuroinflammation, mTOR pathway, oxidative stress, and synaptic remodeling.

Validated Preclinical Data

Superior efficacy of combinations over single agents demonstrated in established animal models of epilepsy.

Translational Excellence

Collaborating with Harvard, UCL, Hannover, Paracelsus, and Rutgers to translate breakthroughs into clinical programs.

Interested in our pipeline?

Learn more about the world-class team driving these programs or get in touch to discuss collaboration opportunities.

Meet the Team Contact Us